Fisetin Targets NUF2 to Block Prostate Cancer Growth via p38/MAPK Pathway
Researchers identify NUF2 as a key driver of prostate cancer and discover fisetin, a natural compound, as a promising inhibitor of this oncogene.
Summary
A new study reveals that NUF2, a protein significantly overexpressed in prostate cancer, drives tumor growth and metastasis through the p38/MAPK signaling pathway. The transcription factor YY1 directly activates NUF2 expression by binding its promoter. Silencing NUF2 reduced cancer cell proliferation and spread in lab and animal models, while overexpression worsened outcomes. Crucially, researchers identified fisetin — a naturally occurring flavonoid found in fruits and vegetables — as a small molecule inhibitor of NUF2. Fisetin suppressed prostate cancer cell growth, and this effect was reversed when NUF2 was overexpressed, confirming on-target activity. NUF2 levels also correlated with poorer patient survival, suggesting its value as both a prognostic biomarker and therapeutic target.
Detailed Summary
Prostate cancer remains one of the most common and deadly cancers affecting men worldwide, yet the molecular mechanisms driving its progression are not fully understood. Identifying new oncogenic drivers and druggable targets is critical for improving patient outcomes, particularly in advanced or treatment-resistant disease.
This study focused on NUF2, a kinetochore complex protein, and found it to be significantly overexpressed in prostate cancer tissue compared to normal tissue. Elevated NUF2 expression correlated with worse patient survival, positioning it as a clinically relevant biomarker. The transcription factor YY1 was identified as a direct upstream activator of NUF2, binding to its gene promoter and amplifying its oncogenic downstream effects.
Mechanistically, NUF2 was shown to promote cancer progression by recruiting p38 kinase, accelerating its phosphorylation, and thereby activating the p38/MAPK signaling cascade — a well-established pathway involved in cell proliferation, survival, and metastasis. Silencing NUF2 in both cell culture and animal models significantly impaired tumor growth and metastatic spread, while NUF2 overexpression had the opposite effect.
Using the PubChem chemical database, the team identified fisetin — a polyphenolic flavonoid naturally present in strawberries, apples, and onions — as a small molecule inhibitor of NUF2. Fisetin effectively inhibited prostate cancer cell proliferation, and this inhibition was reversed by NUF2 overexpression, validating the specificity of the interaction. This positions fisetin, already studied for its senolytic and anti-inflammatory properties, as a candidate therapeutic agent targeting NUF2.
While these findings are promising, the study is primarily preclinical. Validation in human clinical trials will be essential before fisetin or NUF2-targeting strategies can be translated into standard care. Nonetheless, NUF2 emerges as a compelling dual-purpose target — both a prognostic marker and a therapeutic vulnerability in prostate cancer.
Key Findings
- NUF2 is significantly overexpressed in prostate cancer and correlates with poor patient survival.
- Transcription factor YY1 directly binds the NUF2 promoter, activating its oncogenic expression.
- NUF2 drives prostate cancer progression by activating the p38/MAPK signaling pathway.
- Fisetin, a natural flavonoid, was identified as a small molecule inhibitor of NUF2.
- Silencing NUF2 reduced tumor proliferation and metastasis in vitro and in vivo.
Methodology
The study used in vitro cell line models and in vivo animal models to assess NUF2 function via gene silencing and overexpression. Transcriptional regulation by YY1 was confirmed through promoter-binding assays. Fisetin was identified as a NUF2 inhibitor via computational screening of the PubChem database.
Study Limitations
The study is preclinical, relying on cell lines and animal models without human clinical trial validation. The mechanism by which fisetin physically interacts with NUF2 requires further structural and pharmacokinetic characterization. Broader applicability to castration-resistant or metastatic prostate cancer subtypes was not specifically addressed.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.